ROIV Roivant Sciences Ltd.
$36.54▲ +1.36%
Healthcare
Other
After hours
$36.54▲ +0.00%
Oct 27, 4:53 PM ET
Volume 6.57M
Avg Volume (10D) 7.85M
Key Metrics & Fundamentals
Market Cap
$26.39B
P/E Ratio
–
Div Yield
0.00%
52W Range
18.32 - 42.50
% vs 50 MA
-0.29%
% vs 200 MA
16.77%
RSI-14
53.5
MACD Histogram
+0.3100
Beta (1Y vs SPY)
1.02
Free Cash Flow
-$270.92M
Gross Rev
$1.44M
Gross Profit
$1.16M
EBITDA
-$402.81M
COGS
$284,000
Operating Exp
$367.54M
Operating Income
-$366.39M
EBIT
-$366.39M
Pretax Income
-$294.56M
Net Income
-$189.84M
EPS (Diluted)
-0.26
Price & Volume History
Loading chart…
Recent News
Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials
TIKR · Oct 23, 2026 1:25 PM ET
ANI Pharmaceuticals' Eye-Care Franchise Faces New Competition, Oppenheimer Says
MT Newswires · Oct 22, 2026 12:15 PM ET
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results
MarketBeat · Oct 21, 2026 11:04 AM ET
Roivant Sciences stock surges on positive uveitis trial data
Investing.com · Oct 21, 2026 9:09 AM ET
Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis
MT Newswires · Oct 21, 2026 7:40 AM ET
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run
Simply Wall St. · Oct 18, 2026 8:20 PM ET
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Stocktwits · Oct 8, 2026 1:33 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ROIV's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.